Literature DB >> 28534137

[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)].

K Schrör1, S Nitschmann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28534137     DOI： 10.1007/s00108-017-0260-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  4 in total

1.  Imprecision: Limitations to Interpretation of a Large Randomized Clinical Trial.

Authors:  Garret A FitzGerald
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

Review 2.  Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.

Authors:  Patricia McGettigan; David Henry
Journal:  PLoS Med       Date:  2011-09-27       Impact factor: 11.069

3.  Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).

Authors:  Thomas M MacDonald; Chris J Hawkey; Ian Ford; John J V McMurray; James M Scheiman; Jesper Hallas; Evelyn Findlay; Diederick E Grobbee; F D Richard Hobbs; Stuart H Ralston; David M Reid; Matthew R Walters; John Webster; Frank Ruschitzka; Lewis D Ritchie; Susana Perez-Gutthann; Eugene Connolly; Nicola Greenlaw; Adam Wilson; Li Wei; Isla S Mackenzie
Journal:  Eur Heart J       Date:  2017-06-14       Impact factor: 29.983

4.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Authors:  N Bhala; J Emberson; A Merhi; S Abramson; N Arber; J A Baron; C Bombardier; C Cannon; M E Farkouh; G A FitzGerald; P Goss; H Halls; E Hawk; C Hawkey; C Hennekens; M Hochberg; L E Holland; P M Kearney; L Laine; A Lanas; P Lance; A Laupacis; J Oates; C Patrono; T J Schnitzer; S Solomon; P Tugwell; K Wilson; J Wittes; C Baigent
Journal:  Lancet       Date:  2013-05-30       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.